Device Placement for Omnipod and Dexcom
Yes, the Omnipod insulin pump and Dexcom continuous glucose monitor can and should be placed on different sides or locations of the body to avoid potential interference and optimize accuracy.
Rationale for Separate Placement
Evidence for Spatial Separation
Research demonstrates that co-locating insulin delivery and glucose sensing sites may cause minor perturbations in local glycemia measurements. In minipig models, glucose sensors placed 0.5 cm from insulin injection sites showed glycemic readings approximately 3% lower than distant sensors, while sensors at 3 cm showed 11% lower readings compared to sensors placed 10-15 cm away 1.
The study concluded that "caution is warranted when co-locating glucose sensing and insulin injection sites" due to evidence that insulin injection can cause up to 10% perturbation in local subcutaneous glucose readings 1.
Approved Placement Sites
Both the abdomen and upper arm are validated insertion sites for Dexcom CGM sensors with equivalent accuracy. Research comparing Dexcom G4 Platinum sensors on the abdomen versus upper arm found no statistical difference in Mean Absolute Relative Difference (12.3% abdomen vs 12.0% arm, P>0.05) or Clarke error grid zone A placement (85.6% abdomen vs 86.0% arm) 2.
This provides flexibility to place devices on opposite sides or different anatomical locations (e.g., Omnipod on abdomen and Dexcom on arm, or vice versa) 2.
Practical Placement Strategy
Recommended Approach
Place the Omnipod and Dexcom at least 3-10 cm apart to minimize any potential local glycemic interference from insulin delivery affecting CGM accuracy 1.
Utilize different anatomical regions when possible (e.g., one device on abdomen, the other on upper arm) to maximize separation distance and reduce skin irritation from having multiple devices in close proximity 3, 2.
Rotate insertion sites regularly to prevent lipohypertrophy and skin complications, which is standard practice for both insulin delivery and CGM devices 4.
Clinical Context
Integration with Automated Insulin Delivery
Modern hybrid closed-loop AID systems (which include Omnipod and Dexcom integration) are the preferred insulin delivery method for adults and youth with type 1 diabetes, achieving superior time-in-range and reduced hypoglycemia compared to conventional pumps 4, 3.
The spatial separation of devices does not impair the wireless communication between Omnipod and Dexcom systems, as these devices communicate electronically rather than relying on proximity of insertion sites 3.
Common Pitfalls to Avoid
Do not place both devices in the exact same anatomical area (within 3 cm of each other), as this may theoretically affect CGM accuracy during insulin boluses 1.
Monitor for skin irritation at both sites, as prolonged device wear can cause local reactions that may necessitate site changes 3.
Ensure adequate subcutaneous tissue at each insertion site to avoid intramuscular placement, which can cause erratic absorption for insulin and potentially affect CGM accuracy 4.